Abstract
Alzheimer's disease (AD) is a progressive neurological condition characterized by a loss in cognitive functions, with no disease-modifying medication now available. It is crucial for early detection and treatment of Alzheimer's disease before clinical manifestation. The stage between cognitively healthy older persons and AD is known as mild cognitive impairment (MCI). To predict the transition from one-stage MCI to probable AD, five ensemble learning approach was used (Stacking, Gradient boost Bagging, Adaptive boost and Voting), an integrated model that combines not only cross-sectional neuroimaging biomarkers at baseline but also longitudinal cerebrospinal fluid (CSF) and cognitive performance biomarkers from the Alzheimer's Disease Neuroimaging Initiative cohort (ADNI). The adaptive boost, stacking and bagging ensemble approach has shown potential to identify those at risk of developing Alzheimer's disease, this would benefit them the most from a clinical trial or to use as a stratification approach inside clinical trials.